Technology Transfer
Product Description
Chime Biologics
-
Country/Region:China
-
Founded:2013
-
On CPHI since:2023
-
Certificates:5
-
Employees:500 - 999
Company types
Primary activities
Categories
Chime Biologics
-
Country/Region:China
-
Founded:2013
-
On CPHI since:2023
-
Certificates:5
-
Employees:500 - 999
Company types
Primary activities
More Products from Chime Biologics (28)
-
Product Quality system
Our top-rated Quality System is designed to meet global regulatory expectation and follows the laws, regulations and rules for CMC activities, including: Requirements of US 21 CFR Part 210, 211, and 600 governing Good Manufacturing Practices (“cGMP”) Requirements of US 21 CFR Part 11 governing ... -
Product Ramucirumab
Ramucirumab biosimilar cdmo -
Product Regulatory Support
We support you with well-versed regulatory service, including consulting/strategic services, scientific advisory meetings, preparing regulatory dossiers and supporting for agency communication/responses preparation.
We have the capabilities and experience of IND/CTA and BLA/MAA/NDA dossier prepa... -
Product Risankizumab
SkyriziCLD initiated -
Product Romosozumab
Romosozumab biosimilar cdmo -
Product Secukinumab
CosentyxCLD ongoing, pool generation ongoing -
Product Trastuzumab Deruxtecan
EnhertuSingle cell cloning ongoing (Pool selectiondone);mAb and ADC process development ongoing -
Product Adalimumab
HumiraCLD ongoing, pool generation ongoing -
Product Biologics Contract Manufacturing
Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologic medicines to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturi... -
Product Blinatumomab
BlincytoCLD initiated -
Product Blinatumomab
BlincytoNMPA IND approved, process at 50Lscale -
Product Cell Line Development
We offer efficient, flexible and high performing mammalian cell line development to transform your research into drug substances
Leveraging the internal expression vector engineering expertise, we have optimized and engineered the proprietary vectors with selection stringency to be used with our...
Chime Biologics resources (8)
-
News Interview: Biosimilars, a Market Reaching an Inflection Point - A Conversation with Frederic Bouvier
Frédéric Bouvier is a senior biopharmaceutical executive with 25+ years of experience in biologics and biosimilars across Sanofi, Fresenius Kabi, biotech startups, and CDMO organizations. His expertise spans corporate strategy, business development, portfolio build-up, and commercialization, with a strong track record of bringing biosimilars to international markets. -
News INTERVIEW WITH PETER PANG: WHERE BIOSIMILAR CMC RISK REALLY SITS TODAY
In this interview, Peter Pang discusses evolving risks and key considerations for biosimilar CMC amid the growing adoption of CES waivers by regulators. -
Brochure Developing a Robust Manufacturing Process for Pre-filled Syringe Biologics
A prefilled syringe (PFS) is a ready-to-use disposable syringe with a premeasured dose, eliminating the need to draw medication from a vial. -
News Chime Biologics congratulates hope medicine inc on successful phase iii clinical dosing
March 2026, Shanghai, China — Chime Biologics, a leading global CDMO that enables its partners' success in biologics, congratulates its partner Hope Medicine Inc. on the successful dosing of the first patient in the Phase III clinical trial of HMI-115, a novel monoclonal antibody developed for the treatment of endometriosis. This milestone was achieved at the lead site, Peking Union Medical College Hospital, in China. The trial is a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the safety and efficacy of HMI-115 in treating moderate to severe pain associated with endometriosis. -
News From China, bridging biopharmaceutical innovation in Korea
Recently, the 2026 Hubei–Korea Future Cooperation Exchange Event was successfully held in Wuhan, China. As an important platform for efficient collaboration between Chinese and Korean industries and capital, the event brought together government agencies, financial institutions, well-known enterprises, and industry representatives from both countries to conduct in-depth exchanges on strategic emerging industries, with a focus on biomedicine.
-
News Chime Biologics at Bio Equity Europe 2026
At this year’s BIO Equity Europe discussions held in Prague, Czech Republic earlier this month, one message resonated consistently across presentations, panels, and investor conversations: the global biotechnology industry is entering a new era defined by artificial intelligence, accelerated innovation efficiency, and strategic global collaboration.
Representing Chime Biologics, Board Director and CEO Jimmy Wei shared the company’s vision in a featured presentation titled “Turning AI into Biologics Reality”, highlighting how Chime Biologics is integrating China’s rapidly advancing AI ecosystem into end-to-end biologics development and manufacturing capabilities.
-
News Chime Biologics, Daewoong Team Up for Global Dupilumab Biosimilar
Wuhan, China & Seoul, South Korea | June 2, 2026 — Chime Biologics, a global biologics CDMO dedicated to enabling partners’ success, and Daewoong Pharmaceutical, a leading South Korean pharmaceutical company, today announced the signing of a strategic partnership agreement for the development and manufacturing of a dupilumab biosimilar candidate referencing Dupixent.